Major Events - HASHKEY HLDGS (03887) plans to conduct an IPO from December 9 to December 12, aiming to globally offer 241 million shares and has secured cornerstone investors including UBS AM Singapore [1] - Tuda Tong (02665) is set to list on December 10 with a share price of HKD 10 [1] - Federated Pharmaceutical (03933) has received approval from the National Medical Products Administration for its moxifloxacin eye drops [1] - Shou Cheng Holdings (00697) has attracted investments from Beijing Robotics Fund and Shou Bao Fund for its subsidiary Yun Shen Chu Technology [1] - Botai Car Link (02889) has been selected by a leading OEM in the new energy vehicle sector as the supplier for the next-generation smart car cockpit project [1] - Guangdong-Hong Kong-Macau Holdings (01396) subsidiary Tiandun Data has signed a strategic cooperation agreement with Huagong Technology (000988.SZ) [1] Operating Performance - China Life Insurance (02628) reported total premiums exceeding CNY 700 billion by the end of November [1] - Datang Renewable (01798) achieved a cumulative power generation of approximately 31.6521 million MWh in the first 11 months, representing a year-on-year increase of 10.58% [1] - Longfor Group (00960) recorded total contract sales of CNY 59.39 billion in the first 11 months [1] - China Jinmao (00817) reported a cumulative contracted sales amount of CNY 100.679 billion in the first 11 months, reflecting a year-on-year growth of 21.3% [1] - New Town Development (01030) reported a cumulative contract sales amount of approximately CNY 17.917 billion in the first 11 months, a year-on-year decrease of 51.53% [1] - CIFI Holdings Group (00884) achieved a cumulative contract sales amount of approximately CNY 15.1 billion in the first 11 months [1]

Core Viewpoint - The approval of Moxifloxacin Hydrochloride Eye Drops by the National Medical Products Administration of China marks a significant advancement for the company in the ophthalmic product sector, enhancing its competitive position in the field of anti-infective treatments [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Zhuhai United Pharmaceutical Co., Ltd., received approval for Moxifloxacin Hydrochloride Eye Drops in two specifications: 0.5% (3ml: 15mg) and 0.5% (5ml: 25mg) [1] - The drug is classified as a fourth-generation fluoroquinolone with broad-spectrum antibacterial activity, effective against bacteria such as Staphylococcus aureus and Haemophilus influenzae [1] Group 2: Market Position and Future Plans - The product is included in the National Medical Insurance Directory (2024 edition) as a Class B drug, indicating its importance in the healthcare system [1] - The approval is expected to expand the company's ophthalmic product portfolio and strengthen its position in the anti-infective treatment market [1] - The company aims to continue advancing new product development to provide comprehensive and high-quality medication solutions, which is anticipated to generate greater returns for the company and its shareholders [1]

Core Viewpoint - The approval of Moxifloxacin Hydrochloride Eye Drops by the National Medical Products Administration of China marks a significant advancement for the company in the ophthalmic product sector, enhancing its competitive position in the field of anti-infection treatments [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Zhuhai United Pharmaceutical Co., Ltd., has received approval for Moxifloxacin Hydrochloride Eye Drops in two specifications: 0.5% (3ml: 15mg) and 0.5% (5ml: 25mg) [1] - The drug approval numbers are: National Drug Approval Code H20256128 and H20256129 [1] Group 2: Product Characteristics - Moxifloxacin Hydrochloride is classified as a fourth-generation fluoroquinolone with broad-spectrum antibacterial activity [1] - The eye drops are indicated for the treatment of bacterial conjunctivitis caused by sensitive microorganisms such as Staphylococcus aureus, Haemophilus influenzae, and Chlamydia trachomatis [1] - The product is preservative-free, minimizing the toxic effects of preservatives on ocular tissues, making it suitable for a wide range of patients [1] Group 3: Market Position and Future Outlook - The eye drops are included in the National Medical Insurance Directory (2024 version) as a Class B drug, which may enhance market access and reimbursement potential [1] - This approval is expected to further expand the company's ophthalmic product portfolio and strengthen its position in the anti-infection treatment sector [1] - The company is committed to advancing new product development to provide comprehensive and high-quality medication solutions for clinical use, which is anticipated to generate greater returns for the company and its shareholders [1]

Core Viewpoint - Federal Pharmaceutical's subsidiary has received approval for Moxifloxacin Hydrochloride Eye Drops, expanding its ophthalmic product portfolio and reinforcing its position in the ocular anti-infection treatment sector [1] Group 1: Product Approval - The Moxifloxacin Hydrochloride Eye Drops (0.5% in 3ml: 15mg and 0.5% in 5ml: 25mg) have been approved by the National Medical Products Administration of China, with approval numbers H20256128 and H20256129 [1] - Moxifloxacin Hydrochloride is a fourth-generation fluoroquinolone with broad-spectrum antibacterial activity, effective against bacteria causing bacterial conjunctivitis [1] Group 2: Market Position and Strategy - The product is included in the National Medical Insurance Directory (2024 version) as a Class B drug, indicating its accessibility to a wide patient population [1] - The approval is expected to enhance Federal Pharmaceutical's competitive edge in the ocular anti-infection market and contribute to greater returns for the company and its shareholders [1]

有關本集團產品鹽酸莫西沙星滴眼液的最新情況 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 ( 於開曼群島成立之有限公司 ) (股份代號: 3933) 本公告乃由聯邦制藥國際控股有限公司（「本公司」）自願發出。 本公司董事會（「董事會」）欣然公佈，本公司全資附屬公司珠海聯邦制藥股份有限公 司中山分公司申報的鹽酸莫西沙星滴眼液（規格：0.5%（3ml:15mg）、0.5%（5ml:25mg）） 通過中國國家藥品監督管理局上市審批，藥品批准文號分別為：國藥准字 H20256128、 國藥准字 H20256129。 鹽酸莫西沙星屬於第四代喹諾酮類藥物，具有廣譜的抗菌活性。鹽酸莫西沙星滴眼液 適用於治療金黃色葡萄球菌、流感嗜血桿菌、沙眼衣原體等敏感微生物引起的細菌性 結膜炎。該產品不含防腐劑，避免了抑菌劑對眼組織的毒性作用， ...

Investment Rating - The report maintains an "Outperform" rating for the company [2][7]. Core Insights - The company reported a revenue of 72 million yuan for 2024, representing a year-on-year growth of 20.8%, and a net loss attributable to shareholders of 45 million yuan [7]. - In Q1 2025, the company achieved a revenue of 16 million yuan, with a slight year-on-year growth of 1.9%, and a net loss of 8 million yuan [7]. - The key project NL003 has successfully completed Phase III clinical trials for ulcer and resting pain, with results meeting expectations, and the new drug application has been accepted by the National Medical Products Administration [7]. - The company is actively preparing for the commercialization of NL003, which is expected to be approved by the end of 2025, and has established a nationwide sales network [7]. - The company is focusing on the development of gene therapy and recombinant protein therapeutic drugs, with a projected peak revenue of 3.7 billion yuan for NL003 by 2034 [7]. Financial Summary - The total revenue projections for the company are as follows: 112 million yuan in 2025, 337 million yuan in 2026, and 965 million yuan in 2027, with corresponding year-on-year growth rates of 56.0%, 199.2%, and 186.9% respectively [6][9]. - The gross profit margin is expected to improve from 61.1% in 2025 to 79.8% in 2027 [6]. - The company anticipates a return on equity (ROE) of 25.5% by 2027, indicating a significant turnaround from negative values in previous years [6].